Trending Up1.1600 (6.7285%)
  • Bid / Lots
    18.3100/ 2
  • Ask / Lots
    18.4200/ 4
  • Open / Previous Close
    17.1300 / 17.2400
  • Day Range
    Low 16.8400
    High 18.6000
  • 52 Week Range
    Low 11.9800
    High 26.1600
  • Volume
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 17.24
09:32 ET29117.21
09:38 ET100016.98
09:50 ET20017.05
09:52 ET60016.98
09:54 ET10016.97
09:56 ET10016.98
10:19 ET10016.92
10:46 ET171417.1
11:09 ET10017.35
11:13 ET10017.4
11:18 ET50017.4
11:27 ET20017.365
12:30 ET10017.72
12:38 ET10017.72
01:06 ET10017.72
01:30 ET30017.79
01:32 ET30017.9
01:46 ET10017.82
01:48 ET35317.845
01:51 ET10017.88
02:15 ET28517.9
02:18 ET30017.9
02:24 ET10017.82
02:26 ET20017.82
02:29 ET30017.885
02:31 ET10017.88
02:36 ET10017.9
02:40 ET127617.77
02:47 ET40017.815
02:49 ET10017.86
02:54 ET20017.89
02:58 ET20017.9
03:00 ET10017.89
03:05 ET20017.82
03:07 ET20017.9
03:09 ET153217.88
03:14 ET79317.8
03:16 ET10017.905
03:18 ET39017.77
03:20 ET20017.965
03:21 ET20017.96
03:23 ET40017.965
03:25 ET2308218.56
03:27 ET165218.425
03:30 ET79118.34
03:32 ET40018.49
03:34 ET20018.26
03:36 ET10018.33
03:38 ET24818.4
03:41 ET20018.29
03:45 ET64818.4
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesAURA
Aura Biosciences Inc
United StatesLXRX
Lexicon Pharmaceuticals Inc
United StatesALLK
Allakos Inc
United StatesNUVB
Nuvation Bio Inc
United StatesBLUE
bluebird bio Inc
United StatesINO
Inovio Pharmaceuticals Inc
As of 2022-09-30

Company Information

Aura Biosciences, Inc. is a clinical-stage biotechnology company focused on developing virus-like drug conjugates (VDCs), a novel class of therapies for the treatment of multiple oncology indications. The Company’s lead VDC candidate, AU-011 (belzupacap sarotalocan), consists of a virus-like particle conjugated with an anti-cancer agent. AU-011 consists of human papilloma virus (HPV)-derived VLP conjugated to hundreds of infrared laser-activated molecules. AU-011 selectively targets and destroys cancer cells and activates the immune system with the potential to create long-lasting anti-tumor immunity. AU-011 is in development for ocular cancers, with an ongoing Phase II dose escalation clinical trial evaluating first-line treatment of choroidal melanoma. It seeks to develop AU-011 across its ocular oncology franchise including for the treatment of patients with choroidal metastases. In addition, the Company is developing AU-011 for the treatment of non-muscle invasive bladder cancer.

Contact Information

85 Bolton StreetCAMBRIDGE, MA, United States 02140


David Johnson
Chief Executive Officer, Director
Elisabet de los Pinos
Chief Financial Officer
Julie Feder
Chief Operating Officer
Mark De Rosch
Chief Business Officer
Christopher Primiano

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
Revenue (TTM)
Shares Outstanding
Dividend Yield
Annual Dividend Rate
Ex-Dividend Date
Pay Date
Book Value
P/E Ratio
Price/Sales (TTM)
Price/Cash Flow (TTM)
Operating Margin
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.